Moderna Prepping Covid-19 Vaccine Test Trial
Could there be a vaccine to inoculate people against a coronavirus?
Moderna (MRNA) - Get Report on Monday put in motion plans to see if it might have one.
The Cambridge, Massachusetts-based biotechnology company will begin an experimental trial of a coronavirus vaccine that if successful could eventually help protect individuals from contracting the disease.
The trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, is being funded by the National Institutes of Health, the Associated Press reported, citing an unnamed government official.
According to the AP, testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna. There is no chance participants can get infected from the shots because they don’t contain the virus itself.
Researchers and companies alike are racing to create both a treatment for Covid-19 as well as a potential vaccine to protect people from getting it in the first place.
Shares of Moderna were up nearly 10% at $23.38 in morning trading on Monday.
Catch up on the Latest Videos on TheStreet!
- What to Watch Monday: Fed, Futures and the Debates
- Coronavirus in NYC: How the Pandemic Is Impacting New York City
- How the Federal Reserve's Emergency Rate Cut Impacted Futures
- What March Madness Cancellation Means for College Sports and Your Wallet
- WHO Declares COVID-19 a Global Pandemic: What Is the Coronavirus?
- Will Travel and Tourism Recover From Coronavirus?
- TurboTax Webinar: How to Track Your Tax Refund
- TheStreet Explains: What Is the Fed Funds Rate?
- Retirement Daily: Don’t Retire With Debt: It’s Bad for Your Well-Being
